Statin therapy prevents the onset of Parkinson disease in patients with diabetes

Annals of Neurology

Volumn 80, Issue 4, 2016, Pages 532-540

  Lin, Kun Der ^a,b,c   Yang, Chun Yuh ^d   Lee, Mei Yueh ^a,b,c   Ho, Shu Chen ^d   Liu, Ching Kuan ^a,c   Shin, Shyi Jang ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INCOME; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SOCIOECONOMICS; TAIWAN; TAIWANESE; TREATMENT DURATION; AGED; COMORBIDITY; PROTECTION; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA;

AGED; COMORBIDITY; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PARKINSON DISEASE; PROTECTIVE FACTORS; TAIWAN;

EID: 84981294896     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24751     Document Type: Article

References (32)

1. Friedman B, Lahad A, Dresner Y, Vinker S. Long-term statin use and the risk of Parkinson's disease. Am J Manag Care 2013;19:626–632.
2. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015;386:896–912.
3. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003;53(suppl 3):S49–S58; discussion S58–S60.
4. Kotagal V, Albin RL, Muller ML, et al. Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology 2014;82:1514–1520.
5. Schernhammer E, Hansen J, Rugbjerg K, et al. Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 2011;34:1102–1108.
6. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson's disease. Diabetes Care 2011;34:910–915.
7. Di Napoli P, Taccardi AA, Oliver M, De Caterina R. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 2002;23:1908–1921.
8. Ojha S, Javed H, Azimullah S, Haque ME. β-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease. Mol Cell Biochem 2016;418:59–70.
9. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Statin use and the risk of Parkinson disease. Neurology 2008;70(16 pt 2):1418–1422.
10. Wang Q, Yan J, Chen X, et al. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 2011;230:27–34.
11. Undela K, Gudala K, Malla S, Bansal D. Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. J Neurol 2013;260:158–165.
12. Samii A, Carleton BC, Etminan M. Statin use and the risk of Parkinson disease: a nested case control study. J Clin Neurosci 2008;15:1272–1273.
13. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007;69:1688–1695.
14. Driver JA, Smith A, Buring JE, et al. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2008;31:2003–2005.
15. Huang X, Alonso A, Guo X, et al. Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study. Mov Disord 2015;30:552–559.
16. Huang X, Abbott RD, Petrovitch H, et al. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 2008;23:1013–1018.
17. Roy A, Pahan K. Prospects of statins in Parkinson disease. Neuroscientist 2011;17:244–255.
18. Sun Y, Chang YH, Chen HF, et al. Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care 2012;35:1047–1049.
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.
20. Halanych JH, Safford MM, Keys WC, et al. Burden of comorbid medical conditions and quality of diabetes care. Diabetes Care 2007;30:2999–3004.
21. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disorders 2010;16:79–84.
22. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
23. Wolozin B, Wang SW, Li NC, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007;5:20.
24. Lee YC, Lin CH, Wu RM, et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 2013;81:410–416.
25. Sheng Z, Jia X, Kang M. Statin use and risk of Parkinson's disease: A meta-analysis. Behav Brain Res 2016;309:29–34.
26. Wang Q, Tang XN, Wang L, et al. Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. Neurosci Lett 2006;408:189–193.
27. Gordon PH, Mehal JM, Holman RC, et al. Incidence and prevalence of Parkinson's disease among Navajo people living in the Navajo nation. Mov Disord 2015;30:714–720.
28. Augustine EF, Perez A, Dhall R, et al. Sex differences in clinical features of early, treated Parkinson's disease. PLoS One 2015;10:e0133002.
29. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:819–824.
30. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006;164:998–1002.
31. Barreto GE, Iarkov A, Moran VE. Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease. Front Aging Neurosci 2014;6:340.
32. Ide K, Yamada H, Umegaki K, et al. Lymphocyte vitamin C levels as potential biomarker for progression of Parkinson's disease. Nutrition 2015;31:406–408.